• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » OncoGenex reports promising preclinical cancer data

OncoGenex reports promising preclinical cancer data

March 5, 2012
CenterWatch Staff

OncoGenex Pharmaceuticals’ compound OGX-427 shows potential for augmenting anti-cancer therapies and delay tumor progression.

OGX-427 is designed to inhibit Heat Shock Protein 27 (Hsp27), which is expressed in many types of cancers including prostate, bladder, breast and non-small cell lung cancer. Overexpression of Hsp27 is associated with treatment resistance and negative clinical outcomes in patients with various tumor types.

The preclinical study of OGX-427 tested whether the Hsp27 inhibitor worked synergistically with Heat Shock Protein 90 (Hsp90) inhibitors to disrupt protein homeostasis and maximally stress cancer cells to improve treatment outcomes. The study showed when Hsp27 was decreased via OGX-427 treatment, the effect of the Hsp90 inhibitors was enhanced and tumor cell death was observed. The authors concluded OGX-427 in combination with Hsp90 inhibitors potentiated the effects of Hsp90, delayed tumor growth and prolonged survival in murine prostate cancer models.

"As cancers become resistant to standard therapies we need to identify new ways to continue to stress and effectively treat them," said Dr. Martin Gleave, director of The Vancouver Prostate Centre at the University of British Columbia and researcher on this study. "This study confirms the potential utility of inhibiting cell-survival proteins like Hsp27 and the potential for OGX-427 to be included in anti-cancer treatment combination strategies."

OGX-427 is currently being evaluated in several ongoing phase I and II studies in prostate and bladder cancers.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing